NAMS

NewAmsterdam Pharma's stock (NAMS) has experienced an upward trend over the past six months. As of May 9, 2026, NAMS stock had increased by 10.4% year-to-date, trading at $38.73, with a 52-week range between $16.79 and $42.00. Key events impacting the stock include the Q1 2026 earnings report where the company reported a loss but topped revenue estimates, corporate updates, analyst ratings reiterating "Buy" or "Overweight" ratings, clinical development updates for the PREVAIL trial, and a public offering that generated net proceeds of $190 million.